All News

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

Infection was a leading cause of death in lower-risk myelodysplastic syndromes (MDS), highlighting the need for vigilant monitoring and preventive strategies.

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Respiratory diseases made up the hospitalizations in older adults after they were exposed to wildfire smoke.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

Mike Fazio, director of value-based care at Navista, Cardinal Health, discusses a trending topic at the 2025 Community Oncology Conference: optimizing oncology care with technology.

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

Results presented on Tuesday at the American Association for Cancer Research annual meeting include data on the combined use of tissue and liquid biopsy, as well as a framework for evaluating multicancer early detection testing.

Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discussed the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.

Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with rheumatoid arthritis (RA).

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) in the management of chronic spontaneous urticaria (CSU), a condition with limited therapeutic options over the past decade.

Mingyang Song, MBBS, ScD, discusses the link between ultraprocessed foods and cancer risk, emphasizing nutrition's role in prevention.

A new survey highlights how the mental toll of loneliness trickles down to have very real physical consequences for patients with chronic illness.

Improving adherence to antiretroviral therapy (ART) in youth living with HIV requires interventions that target both family dynamics and any underlying mental illness.

K. "Vish" Viswanath, PhD, explores the evolution of health misinformation, its sources, and the role of technology in shaping public understanding.

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the need for equitable treatment strategies.

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa.

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a clear-cut strategy, a new review finds.

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung cancer (ES-SCLC).

With artificial intelligence (AI) capabilities freeing up workers and driving billions in gains, pharmacy may soon see a 75% workload drop.

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout on patients' physical activity and quality of life.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.

Kimlin Tam Ashing, PhD, of City of Hope National Medical Center, emphasizes the vital role of community engagement in cancer research, enhancing trust and communication between scientists and communities.

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.